drugset / Trial / NCT03011021

Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes

NCT03011021

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and therapeutic effect of ex-vivo expanded umbilical cord blood regulatory T cells adjunct with Liraglutide on autoimmune diabetes.

Timeline

Start
2017-01
Primary completion
2025-06
Completion
2025-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.2 mg
Subject UCB-Treg Cell therapy 1e+06 cells/kg
Subject UCB-Treg Cell therapy 5e+06 cells/kg
Background Insulin Protein / enzyme biologic